Muscle-derived autologous stem cell therapy (U.S. Stem Cell)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMuscle-derived autologous stem cell therapy (U.S. Stem Cell)

Drug Alias NameAutologous skeletal myoblast therapy (Bioheart)Myoblast-derived autologous stem cell therapy (U.S. Stem Cell)Myoblast-derived autologous stem cell therapy-U.S. Stem CellImplanted autologous skeletal myoblasts (U.S. Stem Cell)Implanted autologous skeletal myoblasts-U.S. Stem Cell +[6]

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Muscle-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Muscle stem cell therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsMyocardial InfarctionCoronary Artery DiseaseHeart Failure

Global Approved IndicationsHeart Failure

Approved Indications in ChinaN/A

Original Approved Country/TerritorySouth Korea

Original Approved Date2016/07/29

Country/TerritoryUnited StatesSouth Korea

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesU.S. Stem Cell

China Registration ClassN/A

Develop Information

Active CompaniesU.S. Stem Cell

Inactive CompaniesBioheart Inc

Active IndicationsHeart Failure

Inactive IndicationsMyocardial InfarctionCoronary Artery Disease

Other Information

ATC CodeV03AX